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Tuberculosis and SARS, China
To the Editor: As part of a cohort study of 83 patients with severe acute respiratory syndrome (SARS) in Beijing, China, we conducted a follow-up study of all the patients by routine medical examination. During the process, 3 patients with chest radiographs consistent with active disease were identified as having pulmonary tuberculosis (TB). Here we describe the 1-year clinical outcome and immune response in these patients.
Demographic details and coexisting conditions are shown in the Table. Patient 1 was a healthcare worker who became infected with SARS-associated coronavirus (CoV) while on duty with SARS patients. After he was transferred to a hospital dedicated to SARS management, pulmonary TB was diagnosed (positive acid-fast bacilli smear on sputum samples). Patients 2 and 3 were known to have cases of pulmonary TB and became infected with SARS-CoV after contact with other patients hospitalized for SARS. These 2 patients were sputum smear-negative for acid-fast bacilli, and diagnosis was made on the basis of previous exposure to TB, relevant symptoms of typical pulmonary TB, chest radiographs consistent with active disease, a positive tuberculin skin test result, and the finding of cavity regression on chest radiographs after anti-TB treatment was initiated. No cultures were obtained for isolation and comparison of Mycobacterium tuberculosis strains (1). All 3 patients had confirmed SARS based on amplification of SARS-CoV RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) from sputum and stool specimens (2). Patients 2 and 3 recovered without complications; patient 1 had the most severe disease and required mechanical ventilation in an intensive care unit before recovering.
Both cellular and humoral immunity were evaluated during the followup of these patients. T-lymphocyte subsets were measured 6 months after disease onset by flow cytometry using fluorescein isothiocyanate-labeled specific monoclonal antibodies. Compared to other SARS patients (n = 47), the 3 patients with TB had lower mean CD4+ T cells (368.4/µL vs. 656.6/µL, respectively; p = 0.05) and lower mean CD8+ T cells (371.0/µL vs. 490.1/µL, respectively; p = 0.39). SARS-CoV immunoglobu-
